TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00542724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Dosage as individually required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Human Insulin
Description: Dosage as individually required
Study: NCT00664209

Intervention type: DRUG
Group type: OTHER
Intervention: clartihromycin, amoxicillin, and omeprazole
Description: clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days

Intervention type: DRUG
Group type: OTHER
Intervention: clartihromycin, amoxicillin, and omeprazole
Description: clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo therapy

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo therapy
Study: NCT01613547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 80 mg/kg/day for 7 days
Study: NCT03074396

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of DialysisNet for doctor
Description: DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of Avatar Beans for patient
Description: Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
Study: NCT01791231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)
Description: A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
Study: NCT02377063

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pressed Juice
Description: Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
Study: NCT02201290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Tablets
Description: Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag PfOS
Description: Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
Study: NCT02413931

Intervention type: OTHER
Intervention: Routine management practices applied
Description: all patients will be treated according to routine procedures, no intervention
Study: NCT03237533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be applied locally on the lesion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be applied locally on the lesion
Study: NCT02672202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: * 60 mg/d - twice before surgery and once a day for post operative days 3-7~* 30 mg/d - once a day for post operative days 1-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: * 75 mg/d - twice a day for post operative days 1-2~* 150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: * non-active - twice before surgery~* non-active - twice a day for post operative days 1-7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * non-active - twice before surgery~* non-active - twice a day for post operative days 1-7
Study: NCT02025751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Nasal Spray
Description: One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
Study: NCT03477019

Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue
Description: consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue
Description: consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
Study: NCT01092078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINT
Description: Motivational interviewing for lifestyle changes associated with treating hypertension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINT
Description: Motivational interviewing for lifestyle changes associated with treating hypertension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigation for colonoscopy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigation for colonoscopy.
Study: NCT04462471

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: I-124 PET/CT lesion dosimetry
Description: I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
Study: NCT03575871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Study: NCT03232099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Wine consumption
Description: After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period without alcohol consumption
Description: After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
Study: NCT03780946

Intervention type: PROCEDURE
Intervention: Magnetic anastomosis for pancreaticojejunostomy
Description: Magnetic anastomosis for pancreaticojejunostomy

Intervention type: PROCEDURE
Intervention: Traditional hand-sewn anastomosis
Description: Traditional manual anastomosis for pancreaticojejunostomy
Study: NCT01825135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: sham stimulation will be applied to the quadriceps
Study: NCT02276079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Aerobic Exercise
Description: Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
Study: NCT01613547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days
Study: NCT01392053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbosacral Massage
Description: Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
Study: NCT01327872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40 mg 2 x 20-mg tablets, orally, fasted
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
Study: NCT05223933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive community case management
Description: CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
Study: NCT00807729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LapCBDE
Description: LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
Study: NCT03386448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine and naltrexone
Description: participants will receive scopolamine and naltrexone in buccal drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo arm
Description: participants will receive placebo medications
Study: NCT01918436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAMS intervention
Description: In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
Study: NCT01327872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40 mg 2 x 20-mg tablets, orally, with food
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
Study: NCT03840798

Intervention type: OTHER
Intervention: Child Abuse Clinical Decision Support system
Description: The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets
Study: NCT01327872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40mg 2 x 20-mg tablets, orally, fasted
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
Study: NCT00879060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: spironolactone 50mg daily
Study: NCT01223430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Si-Ni-Tang/ Placebo of Si-Ni-Tang
Description: The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Si-Ni-Tang/ Placebo of Si-Ni-Tang
Description: The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
Study: NCT02420171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adding insulin to In Vitro culture media
Description: We will add insulin for in vitro culture of human embryos
Study: NCT01323283

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
Study: NCT02419105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: transdermal gel, 75 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: transdermal gel, 75 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol
Description: drink solution, 24000 IU once per month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol
Description: drink solution, 24000 IU once per month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink solution
Description: drink solution, 0 IU Colecalciferol once per month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drink solution
Description: drink solution, 0 IU Colecalciferol once per month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal gel
Description: transdermal gel, 0 mg testosterone daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo transdermal gel
Description: transdermal gel, 0 mg testosterone daily
Study: NCT00552565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezular 15mg
Description: Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezular
Description: Rezular 37.5mg 3xday up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezular
Description: Rezular 75mg 3xday up to 12 weeks
Study: NCT03789474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HUNTLEIGH FLOWTRON ACS900
Study: NCT02929667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Standard 6 weeks titration, starting 10 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard 6 weeks titration.
Study: NCT00259337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine
Description: 0.5 mL, IM
Study: NCT02544360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photoaging mobile app promoting poster campaign.
Description: Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie).
Study: NCT03708081

Intervention type: PROCEDURE
Intervention: ProTaper Next
Description: Root canal instrument

Intervention type: PROCEDURE
Intervention: TF Adaptive
Description: Root canal instrument
Study: NCT03634657

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Plain X-ray protection shield
Description: Coronary angiography with mere X-ray protection shield

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protection shield & X-ray protective strips
Description: Coronary angiography with X-ray protection shield \& X-ray protective strips

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protection shield & protective strips & patient cut-outs
Description: Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
Study: NCT01064310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral anti-angiogenic treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral anti-angiogenic treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: oral anti-angiogenic treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: oral anti-angiogenic treatment
Study: NCT01327872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40 mg 2 x 20-mg tablets, orally, with food
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
Study: NCT02496585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study: NCT00879060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive placebo pill daily
Study: NCT02496585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT04042675

Intervention type: DIAGNOSTIC_TEST
Intervention: observational study
Description: There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
Study: NCT02496585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01826877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdGMCAIX-transduced autologous dendritic cells
Description: Given ID
Study: NCT00694694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin + artesunate
Description: Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
Study: NCT01826877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies